City University of New York (CUNY)

CUNY Academic Works
Student Theses

John Jay College of Criminal Justice

Summer 8-5-2019

The Impact of Cannabis Use on Generalized Anxiety Disorder
Dylan James Tellez
CUNY John Jay College, dylan.tellez@jjay.cuny.edu

How does access to this work benefit you? Let us know!
More information about this work at: https://academicworks.cuny.edu/jj_etds/122
Discover additional works at: https://academicworks.cuny.edu
This work is made publicly available by the City University of New York (CUNY).
Contact: AcademicWorks@cuny.edu

The Impact of Cannabis Use on
Generalized Anxiety Disorder

A thesis submitted to fulfill the requirements for a MA at
City University of New York
John Jay College of Criminal Justice

Dylan James Tellez
Mentored by: Dr. Rebecca Weiss, PhD
July 2019

CANNABIS USE STATUS CHANGE AS A PREDICTOR OF GAD

2

Table of Contents
Introduction ................................................................................................................................ 4
Cannabis Use and Mental Health ............................................................................................. 7
Generalized Anxiety Disorder and Cannabis ........................................................................... 9
Impact of Sociodemographic Characteristics ......................................................................... 13
This Study ............................................................................................................................. 15
Method ..................................................................................................................................... 16
Participants ........................................................................................................................... 16
Measures ............................................................................................................................... 19
Other substance use. .............................................................................................................................. 21
Family history ......................................................................................................................................... 21
Mental health treatment. ....................................................................................................................... 21
History of other disorders ..................................................................................................................... 22
Cannabis use disorder ........................................................................................................................... 22
Target Variable: Cannabis use status ..................................................................................... 22
Outcome variable: Generalized anxiety disorder (GAD) ........................................................ 23
Analytic Plan ........................................................................................................................ 23
Results ...................................................................................................................................... 24
Secondary Findings ............................................................................................................... 25
Discussion................................................................................................................................. 30
References ................................................................................................................................ 34

CANNABIS USE STATUS CHANGE AS A PREDICTOR OF GAD

3

Abstract
Cannabis is the most commonly used illicit substance in the world (United Nations Office on
Drugs and Crime, 2018). Despite past criminalization, various states have begun to decriminalize
cannabis for recreational and medical use; however, research on the effect of cannabis use on
mental health is divided. Research on specific mental health disorders, like generalized anxiety
disorder (GAD), and cannabis use is lacking. This study aimed to understand whether cannabis
use affected individuals likelihood of meeting criteria for GAD by using a nationally
representative longitudinal dataset. Results indicated that the inclusion of cannabis use did not
explain additional variability in meeting criteria for GAD, suggesting that the relationship
between GAD and cannabis use is not a straightforward causal relationship. Secondary analysis
indicated history of anxiety or mood disorder and seeking mental health were significant
predictors at all levels of GAD. Findings highlight the need to further explore the etiology of
cannabis use and GAD.
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Changes in Cannabis Use as a Predictor of Generalized Anxiety Disorder
Introdu ction

Cannabis has consistently been the most commonly used illicit drug in the United States
(Substance Abuse and Mental Health Services Administration [SAMHSA], 2018a) and the world
(United Nations Office on Drugs and Crime, 2018). A comparison of drug use incidence in the
United States revealed an increase in users who reported using cannabis in the past year, from
10.88% in 2008-2009 to 14.5% in 2016-2017 (SAMHSA, 2018b). Similarly, SAMHSA (2018a)
estimated that cannabis use increased among all individuals over the age of 12 in the United
States, up to 40 million users in 2017 from 37 million users in 2016. The greatest increase in new
cannabis users was observed in the 12-25 age group, which yielded 667 million new users in this
timeframe (SAMHSA, 2018a). These substantial increases in new cannabis users were likely
reflective of recent political shifts in the United States. At the time of writing, 33 states and 3
territories had legalized medicinal cannabis, with 14 of those states also legalizing recreational
use of cannabis (National Conference of State Legislatures, 2019). Problematically, the field of
psychology is divided regarding the effect of cannabis use on individuals’ psychiatric symptoms
and its efficacy as a form of treatment.
Using cannabis for medicinal purposes has been traced back to 2000 BCE when it was
described in the earliest Chinese pharmacopeia for various ailments ranging from nausea to
scorpion stings (Newton, 2017). Cannabis was not formally presented as a modern medicine in
Europe until 1839, when it was recommended for treating muscle spasms, vomiting and diarrhea.
Soon after, in 1850, it was added to the United States Pharmacopoeia, which prompted major
pharmaceutical companies like Lilly and Parke-Davis to develop extracts to be sold over the
counter (Brecher, 1972). Cannabis had been considered an antispasmodic, analgesic, anesthetic,
narcotic, and a powerful aphrodisiac. Additionally, it had been indicated to treat or alleviate
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migraines, pain and discomfort of uterine afflictions, whooping-cough, gonorrhea, melancholia,
neuralgia, and dysmenorrhea (Hollister, 2001; Potter, 1917). A meta-analysis examining studies
dated from 1948-1998 found that in studies using cannabis, researchers reported the drug as
effective for a variety of aliments: 70-93% of patients reported an antiemetic effect; 63-90% of
patients reported increases in body weight and caloric consumption; and 60-97% of patients
reported beneficial effects and reduction in spasticity (Hollister, 2001).
Despite the evidence suggesting cannabis’ effectiveness as a medication, Congress began
to pass laws prohibiting its use. Previously known as Indian cannabis, it has been speculated that
cannabis’ association with Mexican immigrants led to the Pure Food and Drugs Act and the
gradual prohibition of the drug (Gieringer, 1999). The Pure Food and Drugs Act was established
in 1906 and identified cannabis as an intoxicating ingredient. As a result, all products that
contained cannabis were required to mention the ingredient on the product’s label. Several years
later, the Harrison Act of 1914 created a tax on the production and distribution of cocaine and
opium. An earlier draft of the Harrison Act included a tax on cannabis, which was later dropped
due to its unpopularity with pharmaceutical manufactures (Gierigner, 1999). Eighteen years
later, The Uniform Narcotic Drug Act (1932) was passed, which was the first federal legislation
that explicitly mentioned cannabis in its text. The Uniform Narcotic Drug Act’s purpose was to
encourage states to adopt laws in line with the Narcotic Import and Export Act of 1922, which
limited the distribution of cocaine and opiates. The Uniform Narcotic Drug Act of 1932
contained a provision that added the distribution of cannabis to other drugs including cocaine and
opiates and called for penalties to include fines and imprisonment (Anslinger & Tompkins,
1953). In 1937, the Marihuana Tax Act created cumbersome regulations and taxes and required
individuals involved with the production, sale, or consumption of cannabis to register with the

CANNABIS USE STATUS CHANGE AS A PREDICTOR OF GAD

6

federal government and pay a tax for each portion of the process. Each new law eroded cannabis’
status as a medical treatment until finally Congress passed the Controlled Substances Act of
1970 (CSA). The CSA outlawed possession or distribution of drugs, classified cannabis as a
Schedule I Drug (indicating it has a high potential for abuse and no medicinal value), imposed
hefty fines and substantial imprisonment for selling and using cannabis, and created the Drug
Enforcement Agency to ensure adherence to the law (Newton, 2013).
Perhaps in response to the looming prohibition, shortly prior to the CSA passage
recreational use of cannabis sharply increased (Reinarman, Nunberg, Lanthier & Heddleston,
2011). In addition to the increase in recreational use, scientific interest increased as well; in
1964, scientists discovered the chemical structure of the psychoactive ingredient in cannabis,
delta-9 tetrahydrocannabinol (THC). This discovery fueled research into the potential for
cannabis related treatment for various conditions, as well as its potential side effects (Reinarman
et al., 2011). Although cannabis’ classification as a Schedule I substance by the CSA halted
research in the United States, the research continued internationally. On the basis of continued
empirical evidence of cannabis’ medicinal properties, California became the first state to pass a
medicinal cannabis use law in 1996 (California Compassionate Use Act of 1996). The law,
although counter to federal regulation, allowed for patients to use cannabis for medicinal
purposes with a physician’s recommendation.
Traditionally, medicinal cannabis has been considered a treatment for symptoms of
serious and often terminal medical conditions like HIV/AIDS and cancer. A survey of patients in
California using cannabis for medicinal purposes revealed this was no longer the case
(Reinarman et al., 2011). Although physical ailments were among the most commonly cited
benefits, mental health issues—including depression, anxiety and insomnia—were also among
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the most commonly cited reasons for use. Moreover, the study found that 50.9% of the sample
used cannabis as a substitute for prescription medication. The degree to which this increased
usage represented sound medicinal practice or over-prescription is unclear. It is important,
however, to consider that Reniarman et al. (2011) collected the information from for-profit
evaluation clinics in California and therefore the data may not be representative of individuals
who use cannabis without a medicinal card and cannot afford an evaluation for a medicinal
cannabis card.
Cannabis Use and Mental Health
The existing literature on the relationship between cannabis use and mental health is
inconclusive, although most researchers agree there is a relationship. The direction of the
relationship, however, is difficult to identify as some studies have found benefits of cannabis use
and others have found no relationship or detrimental effects (for a review, see Whiting et al.,
2015). THC has been linked to the release of dopamine, a neurotransmitter related to the
noradrenergic system, which when dysregulated has been implicated in several mental health
conditions (Carvalho & Van Bockstaele, 2012; Tanda, Pontieri, & Chiara, 1997). Several
researchers have attempted to understand the nature of the relationship between cannabis use and
mental health by using longitudinal data. McGee, Williams, Poulton, and Moffitt (2000) used
longitudinal data from a birth cohort study in New Zealand to examine the relationship between
cannabis use and mental health for individuals at ages 15, 18, and 21. The authors began
collecting information on participants when they were 3, and again every two years until age 15,
after which they followed-up at age 18 and 21; only data from ages 15, 18, and 21 were used in
their study. The authors found that having a mental illness and reporting cannabis use at 15 was
associated with coming from a family with low socioeconomic status, and that those who had a
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mental illness at 15 were four times more likely to report cannabis use than those without a
mental illness. They also found that using cannabis at age 15 did not predict mental health
problems at 18, and that earlier cannabis use was not associated with an increased risk of a later
anxiety disorder or depressive disorder. Further, mental health issues at 18 were predicted by
having an earlier mental health issue, daily smoking and alcohol use, and low parental
attachment. The authors suggested that the relationship between cannabis use and mental health
reflected shared etiologies stemming from socio-economic disadvantage, behavior problems in
childhood and low attachment to parents (McGee et al., 2000). The findings suggest mental
health concerns may precede risk of cannabis use and that other systemic (e.g., socioeconomic
status) and individual factors (e.g., age) may exacerbate the relationship between cannabis use
and mental health issues. However, the study relied on a birth cohort from 1972-1973, which
may not be representative of the current population, and used dated diagnostic criteria for mental
health classifications that may not reflect current mental health standards.
On the other end of the mental health spectrum, a recent review by Hahn (2018)
examined the potential for treating cannabis users who experienced recent-onset of psychosis.
Hanh (2018) reviewed the research that suggested individuals with schizophrenia who were
cannabis abusers had a worse prognosis due to THC’s effect on psychotic symptoms and
cognitive functioning. However, Hanh’s (2018) focus in the review was the effect of cannabidiol
(CBD), a phytocannabinoid found in cannabis. Hahn found that unlike THC, CBD counteracted
the effects of THC that contributed to the psychotic symptomology when the two were mixed,
and that when CBD was isolated, it was found to alleviate psychotic symptoms in otherwise
unmedicated individuals to a similar level as an antipsychotic medication. Although this review
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provided evidence of the beneficial effects of cannabis, it focused on a specific cannabinoid that
may not be available to all cannabis users.
Fergusson, Horwood, and Swain-Campbell (2002) conducted a more statistically
complex longitudinal study that incorporated frequency of use into their analyses. Fergusson and
colleagues (2002) used data from a 1970’s New Zealand birth cohort that was collected yearly
until age 16, with follow-ups at ages 18 and 21. The authors found that individuals who reported
at least weekly cannabis usage (³ 51 times a year) had significantly increased rates of other illicit
substance use, depression, suicide ideation, and suicide attempts. This relationship remained
significant even after controlling for fixed-effects and time-varying effects. However, these
outcomes varied with age such that younger users were more likely to experience these outcomes
than older users, with the exception of depression for which the association did not vary with
age. It should be noted however, that frequency of use intervals were determined by instances of
use throughout the year and did not incorporate method of use (e.g., smoking vs. edibles) or
amount used per instance (e.g., 1 joint vs. 5 joints). Additionally, similarly to the McGee and
colleagues study (2000), this study used a birth cohort from the 1970s in New Zealand and used
similarly dated measures for mental health classifications. Still, the Fergusson et al. (2002)
finding that frequency of cannabis use was a significant predictor of suicidal ideation and
depression across all age groups, and that age may differentially impact other outcomes suggests
the relationship between cannabis use and mental health differs depending on the mental health
concern.
Generalized Anxiety Disorder and Cannabis
Research on cannabis use and anxiety has mainly focused on social anxiety disorder (e.g.,
Buckner & Schmidt, 2009; Buckner & Zvolensky, 2014; Ecker & Buckner, 2018). As a result,
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there is sparse research on generalized anxiety disorder (GAD) and cannabis use. The limited
available research on the relationship between GAD and cannabis use is inconclusive and often
contradictory, positing two opposing arguments (e.g., Kandel et al.1986; Kandel et al. 1992;
Fergusson & Horwood 1997; McGee et al. 2000). The first of these theories suggests that the
relationship between cannabis use and anxiety are causal, such that cannabis use can negatively
affect or lead to the development of anxiety-related symptoms or anxiety disorders, in addition to
other psychosocial problems. The opposing theory suggests that the relationship between
cannabis use and anxiety is not causal and that the strong relationship is a result other factors that
lead to the development of mental illness and initiation of cannabis use, with cannabis being
commonly used as a coping mechanism (Fergusson et al., 2002; Johnson & Kaplan, 1990).
Crippa and colleagues (2009) conducted a systematic literature review to understand the
clinical, diagnostic, and causal implications of the relationship between cannabis use and
anxiety. Their findings indicated that in infrequent or non-habitual users, cannabis can cause
brief but intense episodes of anxiety, but regular users often reported a reduction of anxiety
symptoms. When compared to non-users, frequent users displayed higher levels of anxiety with
the severity of anxiety symptoms increasing with increased cannabis use (Crippa et al., 2009). It
is important to note that the studies from which these findings came were published over 20
years ago (e.g., 1998) and do not provide explanation of how classification of user status was
determined.
Crippa and colleagues (2009) found that participants who reported cannabis abuse or
dependence also reported higher levels of anxiety. However, these findings were drawn from
studies on adolescence, which can be a socially difficult developmental period, and from
research on indigenous communities in northern Australia, which could have affected the
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external validity of the studies. Still, the authors suggested the relationship between anxiety and
cannabis use was dose dependent, whereby low doses may be beneficial as a treatment option
and larger doses could result in the onset of anxiety-like symptoms. Further, the authors
concluded that the evidence did not support that cannabis use alone was enough for the
development of long-term anxiety but still suggested that cannabis use in conjunction with other
risk factors may lead to the manifestation of anxiety disorders or anxiety-like symptomology
(Crippa et al., 2009). However, since a literature review cannot account for causal relationships,
it is possible that those with increase anxiety symptoms chose to self-medicate (perhaps
ineffectively) with cannabis.
Kedzior and Laeber (2014) conducted a meta-analysis to examine the relationship
between anxiety and cannabis. The authors reviewed 31 studies, and included both longitudinal
and cross-sectional studies in their analyses, highlighting a methodological limitation in the
aggregation of datasets. Moreover, the studies collected by the authors spanned 10 countries
(Australia, Canada, Columbia, France, Germany, Netherlands, New Zealand, Switzerland, UK,
and US) and included participants from the general population, high school students,
adolescents, and undergraduate students, further complicating the interpretation of the results by
failing to parse out age groups and population sectors. The findings of this meta-analysis, which
included 112,000 cases, indicated that cohorts with anxiety had a higher probability of using
cannabis or having a comorbid cannabis use disorder. Additionally, despite not controlling for
acute cannabis use, the results indicated that any level of cannabis use was positively related to
clinically relevant symptoms of anxiety. It is important to note that studies evaluated in this
meta-analysis that used symptom severity scales failed to show a positive association with only
clinical symptoms of anxiety disorders producing this positive association between cannabis use
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and anxiety disorders. The authors concluded that the small magnitude of the association
between anxiety and cannabis use did not support a blanket prohibition of cannabis and noted
that cannabis use was only a minor contributor to the worldwide disease burden (Kedzior &
Laeber, 2014).
Hayatbakhsh and colleagues (2007) took an alternative approach to understanding the
relationship between cannabis use and anxiety and depression, and utilized data from a
longitudinal study of pregnant women and their children initiated in 1981. Findings suggested
that adolescents at the age of 14, whose mothers were diagnosed with anxiety or depression,
smoked cigarettes, or consumed alcohol, had a higher risk of engaging in cannabis use at a later
age. The authors also found that age of initiation and frequency of cannabis use were
significantly associated with anxiety and depressive symptoms, such that those who used
cannabis frequently were significantly more likely to report symptoms of anxiety and depression;
this effect was greater with greater frequency of cannabis use and when initiation of use was
early. Lastly, results indicated that the best predictors for cannabis use at age 21 were adolescent
aggression/delinquency and cigarette use at age 14. Data for this study was generated from
patients who were born in public hospitals in Australia, failing to capture those who were
privately insured and likely of a higher socioeconomic status. Additionally, due to the survey
design, psychosocial information was not collected at the age 14 and 21 follow-up, hindering the
ability to determine the nature of psychosocial consequences on the relationship between
cannabis use and anxiety and depression. Lastly, data on the initiation and frequency of cannabis
use were both collected using self-report measures used only once, during the age 21 follow-up.
The measures were unable to capture many individuals who used cannabis frequently but did not
use other drugs. Moreover, the frequency of cannabis use was measured based on usage in the
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past month, failing to account for periods in which cannabis was used more or less frequently
than reported.
Danielsson, Lundin, Agardh, Allebeck, and Forsell (2016) also conducted a longitudinal
study attempting to identify a relationship between cannabis use, anxiety and depression.
Danielsson and colleagues used data from a Swedish longitudinal cohort study with a three-year
follow-up. Findings indicated those who used cannabis at baseline had a greater relative risk for
depression and anxiety at follow-up; however, this association was not statistically significant
once confounding factors were added to the model. The authors concluded that cannabis use was
not associated with depression or anxiety three years later. It is important to note that the sample
consisted of participants from Sweden, where cannabis use may not be as prevalent as in the U.S.
or other countries (Ter Bogt, Schmid, Nic Gabhainn, Fotiou, & Vollebergh, 2006) and as a result
may limit generalizability. More importantly, the survey that was utilized in this study did not
capture age of initiation or frequency of use. Additionally, between baseline and follow-up time
points, the scale for anxiety was changed, potentially confounding results from the association.
Impact of Sociodemographic Characteristics
The nature of the relationship between anxiety and cannabis use remains unclear and is
only further complicated by the interaction with other sociodemographic factors, like gender.
Research has consistently found that women have a significantly higher likelihood of developing
an anxiety disorder when compared to men (Angst & Dobler-Mikola, 1985; Bruce et al., 2005).
Hayatbakhsh and colleagues (2007) found that women were more likely to experience symptoms
of anxiety by the age of 21. McGee and colleagues (2002) found that having a mental illness at
the age of 18 was predicted by being female. Crippa and colleagues (2009) indicated that genetic
factors that can contribute to anxiety in cannabis users may be enhanced for men. Further, out of
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all anxiety disorders, GAD is the most common among women (De Dios et al., 2010). When
cannabis is added to the relationship between anxiety and gender, it complicates the dynamic and
understanding of the relationship.
In the McGee et al. (2002) study that was previously mentioned, it was found that
cannabis use at age 21 was strongly related to being a man, and cannabis use at the age of 18
predicted having a mental health disorder at the age of 21, but only for men; this finding did not
hold true for women. Patton and colleagues (2002) used longitudinal data from a 7-wave
Australian cohort study and found that frequency of cannabis use was associated with anxiety
and depression but only for women. Specifically, when compared to their male counterparts and
non-users, young women who reported daily cannabis use were five times more likely to report
depression and anxiety, and teenage girls who used cannabis on a weekly basis were two times
more likely to report depression and anxiety. Additionally, De Dios and colleagues (2010) found
that the relationship between cannabis use and anxiety in women was mediated by the
expectation that cannabis would help with anxious symptoms (e.g., relieve stress and tension).
Finally, Aspis and colleagues (2015) compared the quality of life (mental, physical and general)
for three levels of usage, regular (at least weekly), occasional (less than weekly), and no use.
They found that women who used cannabis to self-medicate had greater social and psychological
problems when compared to men. Additionally, women who used cannabis regularly were more
likely to endorse lower health-related quality of life items, more likely to report that emotional or
physical problems interfered with social activities, and more likely to report that they
accomplished less because of emotional problems when compared to non-users; these
differences were not present for men. Taken together these findings speak to the potential
importance of gender in the relationship between anxiety and cannabis use.
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In addition to gender, various other sociodemographic factors have been implicated in the
relationship between GAD and cannabis use. Specifically, Daniel et al. (2009) conducted a
systematic review of the evidence associated with socioeconomic status and drug use and found
that only cannabis use was predicted by lower childhood socioeconomic status. Low
socioeconomic status has also been shown to predict manifestation of anxiety and anxiety-related
symptoms at ages 15 and 21 (Miech, Caspi, Moffitt, Wright & Silva, 1999). Genetics have also
been implicated in cannabis use, such that parental alcohol use predicted later cannabis use and
anxious symptomology (Hayatbakhsh et al., 2007; Crippa et al., 2009).
Lastly, cannabis use disorder must also be considered. Because cannabis use disorder
represents a pathological problem with the use, abuse, or dependency of cannabis use and has
been associated with higher rates of anxiety disorders (Kedzior & Laeber, 2014) it is important to
consider its effect on GAD. Further, one of the symptoms of cannabis withdrawal is an increase
of anxiety-like symptoms including nervousness, restlessness, and shakiness (Budney & Hughes,
2006). These findings highlight the importance of the potential effect of cannabis use disorder on
manifestation of GAD.
This Study
Despite a lack of clear consensus on whether cannabis is beneficial or detrimental to the
manifestation of GAD, studies have found that individuals report using cannabis for relief from
symptoms related to anxiety (e.g., stress and insomnia) (Kedzior & Laeber, 2014; MartinezRodrigues et al., 2008), with some individuals taking it instead of prescription medication
(Reinarman et al., 2011), and that this expectation was a key moderator in the relationship
between cannabis use and anxiety in women (De Dios, et al. 2010). However, the efficacy of
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initiating or desisting from cannabis use as a treatment for anxiety has not been thoroughly
studied.
This study aimed to examine how different cannabis use trajectories predict GAD status.
Specifically, we aimed to understand how continuous use trajectories, switching use trajectories,
or no use trajectories relate to the manifestation of GAD in a nationwide longitudinal study
conducted in the United States. It was hypothesized that cannabis use trajectories would
significantly predict meeting criteria for GAD.
Method
Participants
Data used for this study was obtained from the National Epidemiologic Survey on
Alcohol and Alcohol Related Conditions (NESARC; Chen, Yi, Dawson, Stinson & Grant, 2010).
NESARC is a nationally representative longitudinal study that first began in 2001-2002. To
generate a sample that was nationally representative, NESARC employed a multi-stage
probability sampling design. The first step in this process consisted of creating and sampling
primary sampling units (PSU) that were created through an automated process which grouped
adjoining counties based on specified sociodemographic details. Relying on the Census
2000/2001 Supplementary Survey and the Census 2000 Group Quarters Inventory sampling
frame, the process produced a total of 2000 PSUs. Of the initial 2000 PSUs, PSUs with a
population of 250,000 or more were selected, resulting in 655 selected PSUs. The remaining
PSUs were then categorized in each state by sociodemographic characteristics and two PSUs
from each category were selected, adding a total of 254 PSUs. These were then collapsed for a
total of 435 PSUs (305 with populations over 250,000 and 130 of the remaining). Once
completed, housing units were selected systematically with an intentional oversampling in Non-
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Hispanic Black and Hispanic housing units. In the final stage an individual in the housing unit
was selected at random from a list of all home inhabitants over the age of 18 (Chen et al., 2010).
The dataset for this study is the first longitudinal follow-up that began with data
collection in July 2004 and ended in September 2005. NESARC initially conducted 43,093 faceto-face interviews, and in wave 2 conducted 34,653 re-interviews from the initial population,
yielding an 86.7% follow-up rate. Individuals not re-interviewed for wave 2 were not reinterviewed due to institutionalization, death, deportation, mental or physical impairment, or
active duty deployment (37.1%), and inability to locate or refusal to participate (62.9%).
The majority of participants identified as White, (n = 20,161, 58.2% of the sample).
There were more female participants (n = 20,089, 58%) than males (n = 14,564, 42%), and
participants ranged in age from 20 to 89 (M = 49.06, s = 4.159); it should be noted that in wave 1
age became cateogorical after 89, with participants 90 or above representing 0.8% of the sample
at wave 2 (n = 276), for this reason we used age at wave 2. In terms of educational attainment,
the most frequent response (n = 9,452, 27.3%) was obtaining a high school degree or a general
equivalency degree (GED), and the most frequent earning bracket was between $20K and $50K
(n = 12,976, 37.4%; see table 1 below).
Ninety-four percent (n = 32,568) of the sample did not meet criteria for GAD, with the
remaining sample meeting criteria for GAD in wave 1 only (n = 1,295, 3.7%), in wave 2 only (n
= 1,210, 3.49%), or throughout both waves (n = 340, 0.98%). Only 6.6% (n = 2,275) of the
general sample reported cannabis use in either or both waves (see Table 2 and Table 3 below).
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Table 1
Socio-Demographic Descriptives by Gender
Women

%

Men

%

Total

%

Age
20-90
90+

19,882
207

98.97%
1.03%

14,495
69

99.53%
0.47%

34,377
276

99.20%
0.80%

Ethnicity
White
Black
American Indian/Alaska Native
Asian/Native Hawaiian/Other Pacific Islander
Hispanic

11,308
4261
338
542
3640

56.29%
21.21%
1.68%
2.70%
18.12%

8,853
2,326
240
426
2,719

60.79%
15.97%
1.65%
2.93%
18.67%

20,161
6,587
578
968
6,359

58.18%
19.01%
1.67%
2.79%
18.35%

Personal Income
No Income
Below Federal Poverty Line (>$13K)
$13K->$20K
$20K->$50K
$50K->$80K
$80K ->$100K
+100K

6,898
1,207
2,833
6,811
1,747
241
352

34.34%
6.01%
14.10%
33.90%
8.70%
1.20%
1.75%

2,507
183
1,561
6,165
2,477
620
1,051

17.21%
1.26%
10.72%
42.33%
17.01%
4.26%
7.22%

9,405
1,390
4,394
12,976
4,224
861
1,403

27.14%
4.01%
12.68%
37.45%
12.19%
2.48%
4.05%

Educational Level
No Formal Schooling
Did not complete middle school
Did not complete high school
Obtained HS diploma or GED
Did not complete college
Obtained associates or technical degree
Obtained bachelor’s degree
Obtained post-grad degree
Totals (N = 34,563)

87
791
2,371
5,553
4,355
2,043
3,307
1,582
20,089

0.43%
3.94%
11.80%
27.64%
21.68%
10.17%
16.46%
7.87%
58.00%

57
546
1,662
3,899
3,047
1,341
2,630
1,382
14,564

0.39%
3.75%
11.41%
26.77%
20.92%
9.21%
18.06%
9.49%
42.00%

144
1,337
4,033
9,452
7,402
3,384
5,937
2,964

0.42%
3.86%
11.64%
27.28%
21.36%
9.77%
17.13%
8.55%

Table 2
GAD Status by Cannabis Use Status
No Cannabis
Use in
Either Wave
No GAD
29,852
GAD Throughout
301
GAD in Wave 1 only
1,146
GAD in Wave 2 only
1,079
Total
32,378

Cannabis Use
in Wave 1
Only
493
5
36
29
563

Cannabis Use in
Wave 2 Only

Cannabis Use in
Wave 1 & 2

Total

864
17
58
57
996

599
17
55
45
716

31,808
340
1,295
1,210
34,653

CANNABIS USE STATUS CHANGE AS A PREDICTOR OF GAD

19

Table 3
Predictors by Gender
Sought Mental Health Help SLI
No
Yes
Sought Substance Use Help SLI
No
Yes
Nicotine Dependence
No
Yes
History of Other Use Disorder
No
Yes
History of Family Addiction
No
Yes
History of Family Alcoholism
No
Yes
Cannabis Use Disorder
No
Yes
General Anxiety Disorder Status
No GAD
GAD Throughout
GAD in Wave 1
GAD in Wave 2
Cannabis Use Status
No Use During Either Wave
Use in Wave 1 Only
Use in Wave 2 Only
Use During Both Waves

Women

%

Men

%

Total

%

17,569
2520

87.46%
12.54%

13,673
891

93.88%
6.12%

31,242
3411

90.16%
9.84%

19,972
117

99.42%
0.58%

14,429
135

99.07%
0.93%

34,401
252

99.27%
0.73%

16,208
3881

80.68%
19.32%

10,888
3676

74.76%
25.24%

27,096
7557

78.19%
21.81%

13,107
6982

65.24%
34.76%

10,197
4367

70.02%
29.98%

23,304
11349

67.25%
32.75%

17,049
3040

84.87%
15.13%

12,811
1753

87.96%
12.04%

29,860
4793

86.17%
13.83%

13,107
6,982

65.24%
34.76%

10,197
4367

70.02%
29.98%

23,304
11349

67.25%
32.75%

18,914
1,175

94.2%
5.8%

12,638
1,926

86.8%
13.2%

31,552
3,101

91.1%
8.9%

18,552
160
392
985

92.35%
0.80%
1.95%
4.90%

14,016
51
143
354

96.24%
0.35%
0.98%
2.43%

32,568
211
535
1339

93.98%
0.61%
1.54%
3.86%

19,192
254
391
252

95.53%
1.26%
1.95%
1.25%

13,187
308
605
464

90.55%
2.11%
4.15%
3.19%

32,379
562
996
716

93.44%
1.62%
2.87%
2.07%

Measures
Sociodemographic variables included ethnicity, sex, past year personal income, age,
educational level and family background items relating to addiction history, alcohol use, and
cannabis use.
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NESARC employed the Alcohol Use Disorder and Associated Disabilities Interview
Schedule-DSM-IV (AUDADIS-IV; Grant & Dawson, 2000), a structured diagnostic interview
designed to be administered by laypeople. The AUDADIS-IV operationalized the Diagnostic and
Statitistcal Manual version-IV (Americann Psychiatric Assocation, 2013) criteria for alcohol
abuse and dependence, substance-specific abuse and dependence, mood disorders and anxiety
disorders. The AUDADIS-IV includes an extensive list of symptom questions that operationalize
criteria for drug-specific abuse and dependence for sedatives, tranquilizers, opiates (not
including heroin or methadone), stimulants, hallucinogens, cannabis, cocaine, and
inhalants/solvents, major depression, dysthymia, mania, hypomania, panic disorder (with and
without agoraphobia), social phobia, specific phobia, and GAD. For a more thorough review see
Grant et al (2004).
Sociodemographic covariates. To control for the effect of sociodemographics, ethnicity,
sex, and age were incorporated into the model. Highest completed education level and personal
income in the past year were used to control for socioeconomic status by proxy. In the
AUDADIS-IV, highest level of education was a 14-item categorical response set. For this study
the 14 categories were collapsed into 8 items: 1 - No formal schooling; 2 – did not complete
middle school; 3 – did not complete high school; 4 – obtained high school degree or GED; 5 –
attended but did not complete college; 6 – obtained associates or technical degree; 7 – obtained
bachelor’s degree; or 8- obtained post-grad degree. The obtained high school degree or GED
group was selected as the reference group for the level of education as it represented the mode
for the sample. Income for past year was collapsed from 17 items into 6 items: 1 – no income; 2 below the federal poverty line (>$13k); 3 – earning above $13k but below $20k; 4 – earning
above $20k but below $50k; 5 - earning above $50k but below $80k; 6 - earning above $80k but
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below $100k; and 7 - above $100k. Below the federal poverty line was selected as the reference
group for income level because it is the lowest of income levels and thus represents the lowest
SES.
Other substance use. Use of other substances including both illicit (e.g., amphetamines)
and licit (e.g., cigarettes) drugs have been associated with cannabis use (Fergusson et al., 2002)
and the manifestation of mental health issues (McGee et al., 2002; Hayatbakhsh et al., 2007). To
control for the effect of other substance use, two variables were created: nicotine dependence and
history of other substance use disorders. Nicotine dependence was created by combining wave 1
diagnostic “lifetime nicotine dependence” and wave 2 diagnostic “nicotine dependence since last
interview”. To address the history of other substance use disorders the wave 2 lifetime diagnostic
classifications were used for alcohol abuse/dependence, sedative use disorder, tranquilizer use
disorder, opioid use disorder, amphetamine use disorder, hallucinogen use disorder,
inhalant/solvent use disorder, heroin use disorder, and other drug use disorder. Each variable was
coded as absent (0) or present (1).
Family history. History of family alcohol addiction was created by combining the
responses to “In your judgment, has your blood or natural ______ been an alcoholic or problem
drinker at ANY time in his/her life?” for father, mother, full brother, and full sister. History of
family substance abuse history was similarly created, using the questions “In your judgment, has
your blood or natural _____ had problems with drugs at ANY time in his/her life?” for father,
mother, full brother, and full sister. Each variable was coded as absent (0) or present (1).
Mental health treatment. Because the dataset is longitudinal in nature, the possibility
that participants sought help for mental health or substance use must be considered. To address
the potential for seeking help with substance issues we used the question “since the last interview
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did you seek help because of medicine or drug use?” The seeking help for mental health variable
was created by combining seven versions of “since the last interview did you go to a
counselor/therapist/doctor/psychologist/other person for help” for major depression, dysthymia,
bipolar disorder, panic disorder and agoraphobia, social phobia, specific phobia, and GAD. Each
variable was coded as absent (0) or present (1).
History of other disorders. GAD is often co-morbid with other disorders, to account for
the effect of mood disorders, a variable was created for history of mood disorders. The
AUDADIS-IV provides diagnostic classification for major depression, dysthymia, manic
depression, and hypomanic disorder within their lifetime. The variable then was coded as absent
(0) or present (1) for any of these diagnoses.
A variable was also created to account for the effect of anxiety disorders. Similar to the
mood disorders, the diagnostic classifications for panic disorder with and without agoraphobia,
agoraphobia, social phobia, and specific phobia were coded as absent (0) or present (1) to create
this variable.
Cannabis use disorder. The AUDADIS-IV assesses cannabis use disorder as cannabis
use dependency, cannabis abuse, or cannabis abuse and dependency for both waves. In wave 1,
we used questions that asked whether the participant experienced the criteria for cannabis abuse,
dependency or abuse and dependency during the last 12 months and prior to the last 12 months
coded as absent (0) or present (1). In wave 2, questions that asked whether the participant
experienced the criteria cannabis abuse, dependency, or abuse and dependency since the last
interview or in their lifetime were also coded as absent (0) or present (1).
Target Variable: Cannabis use status. Cannabis use status trajectories consisted of four
use categories: (a) cannabis use throughout (coded as 0); (b) cannabis use in wave 1 only (coded
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as 1); (c) cannabis use in wave 2 only (coded as 2); and (d) no cannabis use throughout the study
(coded as 3). This variable was created using the “did you use marijuana in the last 12 months
only, before the last 12 months only, or during both periods,” question in wave 1, and the “used
cannabis since last interview,” question in wave 2. Each of these variables was coded as absence
(0) or presence of use (1). These scores were then used to determine participants’ cannabis use
status trajectories. Where absence for both items resulted in no use throughout the study;
presence for both items resulted in use throughout; and absence/presence patterns corresponding
with waves 1 and 2 resulted in corresponding use status of use in wave 1 or wave 2, only.
Outcome variable: Generalized anxiety disorder (GAD). GAD status consisted of four
GAD levels: (a) no GAD in either wave (coded as 0); b) GAD in wave 1 (coded as 1); c) GAD in
wave 2 (coded as 2); and d) GAD throughout (coded as 3). This variable was created using the
“generalized anxiety in the last 12 months illness-induced and substance-induced ruled out”
diagnostic categorization in both waves, and the “generalized anxiety since last interview”
diagnostic category from wave 2. Each of these variables was coded as absent (0) or present (1).
These scores were then used to determine participants’ GAD status. Where absence for both
items resulted in No GAD throughout, presence for both items resulted in GAD throughout, and
absence/presence patterns corresponding with waves 1 and 2 resulted in corresponding GAD
status in wave 1 and 2, only.
Analytic Plan
Multinomial logistic regressions were performed to examine the association between
GAD and cannabis use, including a null model with all controls, and a full model that included
the target predictor, cannabis use status trajectories. Several covariates were included to control
for confounding variables including ethnicity, sex, age, personal income for the past year,
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educational level, history of other substance use disorder, cannabis use disorder, help sought for
substance use since last interview, help sougnt for mental health since last interview, family
addiction history, family mental health history, family alcohol abuse history and cannabis use
status. Multinomial logistic regressions allow for comparisons of categorical comparisons (e.g.,
cannabis use status and GAD status) while controlling for the effect of other variables.
Results
A multinomial logistic regression was run where the dependent variable of GAD status
(No GAD throughout, GAD wave 1, GAD wave 2, or GAD throughout) was predicted by
cannabis use status, while controlling for the effects of ethnicity, sex, past year personal income,
educational status, family addiction and alcohol history, nicotine dependence, and cannabis use
disorder. This model was then compared to a null model containing all predictors without the
target variable. When compared to the null model, the cannabis model had a higher Akaike
information criterion (13,422; 13,966, repectively); a higher Baysian information criterion
(14,132; 14,752, respectively); a worse chi-square (χ2(81) = 5,214, p>.001; χ2(90) = 5,223,
p>.001; respectively, p >.001); and a worse log likelihood (13,254; 13,780, respectively).). The
model-fit and information criterion indicate that the null model is a better fit to the data than the
full model which included cannabis use status as the outcome variable. The results are presented
in tables 3, 4, and 5.
The multinomial logistic regression did not find support for the hypothesis. Initiation,
continuance, or cessation of cannabis use did not significantly affect the odds ratio of
progressing from not meeting criteria to meeting criteria for GAD throughout wave 1 and wave 2
or exclusively in wave 1 or wave 2. This is consistent with results of the model comparison
between the null model and cannabis use model, which showed that both models explain the
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same amount of variance in the outcome and that the null model produced the lowest AIC, BIC,
and log likelihood values. Overall, these results suggest the model of best fit would be the most
parsimonious model, the null model, and that cannabis use was not a statistically meaningful
predictor of GAD.
Secondary Findings
Sociodemographic covariates and various control variables were significant predictors at
levels of GAD status. Sociodemographic covariates like ethnicity, education, and income level
were significant only when comparing individuals who did not meet criteria for GAD throughout
to individuals who only met criteria for GAD in wave 1 and wave 2. Specifically, individuals
who were Hispanic (OR = 0.7225 [0.6026, 0.8663], Black (OR = 0.7989 [0.6716, 0.9504]), or
Asian/Native Hawaiian had higher odds (OR = 0.5914 [0.3583, 0.9762) of having GAD in wave
1 when compared to White participants. Although only significant in wave 1, the odds ratios
were comparable at all levels of GAD status. In terms of income level, when compared to
individuals who were earning below the federal poverty line, those who earned between $20K
and $50K (OR = 0.8253 [0.7089, 0.9607]) and $50K and 80K (OR = 0.7749 [0.6176, 0.9721])
had higher odds of meeting criteria for GAD at wave 1 and participants who earned between
$50K and $80K (OR = 0.7002 [0.5436, 0.9018]) had higher odds of meeting criteria for GAD at
wave 2. Lastly, compared to participants who obtained a high school diploma or GED,
participants who obtained a post-grad degree had a 1.331 higher odd ratio of meeting criteria for
GAD at wave 1. These significant findings did not persist when comparing those that did not
meet criteria for GAD throughout the study to those who did in wave 2 or throughout the study.
Each level of GAD status when compared to the reference group, no GAD throughout
had different significant predictors. When compared to participants who did meet criteria for
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GAD throughout, participants who had a family history of addiction (OR = 1.3149 [1.0026,
1.7245]) and sought help for substance use (OR = 2.138 [1.2056, 3.7915]) or mental health
between waves had higher odds of meeting criteria for GAD throughout (OR = 2.0965 [1.8091,
2.4295]). Participants who had a family history of alcoholism (OR = 1.2494 [1.0998, 1.4193]),
history of mood (OR = 5.5467 [4.8773, 6.308]) or anxiety disorder (OR = 3.67 [3.2427,
4.1536]), other substance use disorder (OR = 1.2956 [1.1313, 1.4838]), or sought mental health
between waves (OR = 2.0965 [1.8091, 2.4295]) had higher odds of meeting criteria at wave 1
when compared to participants who did not meet criteria for GAD throughout. Female
participants had greater odds of meeting criteria for GAD at wave 1 (OR = 1.3761 [1.1981,
1.5805]) and wave 2 (OR = 1.5557 [1.3449, 1.7996]). Participants who had a history of anxiety
(OR = 1.3484 [1.1655, 1.56]) or mood disorders (OR = 1.7931 [1.5637, 2.0561]), had a nicotine
dependence (OR = 0.6352 [0.5094, 0.7921]), had a different substance use diagnosis (OR =
1.2335 [1.0676, 1.4252]) or sought mental health help (OR = 11.4722 [10.0834, 13.0523])
had higher odds of meeting criteria for GAD at wave 2 when compared to participants who did
not meet GAD criteria throughout.
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Table 3: Multinomial Logistic Regression Cannabis Model and Null Model
No GAD Throughout compared to GAD Throughout Portion
Cannabis Model
GAD Throughout Intercept
Sex
Hispanic
Black
American Indian/Alaska Native
Asian/Native Hawaiian/Other Pacific Islander
White
No Formal Schooling
Did Not Complete Middle School
Did Not Complete High School
Obtained Post-Grad Degree
Did Not Complete College
Obtained Associates or Technical Degree
Obtained Bachelor’s Degree
Obtained HS Diploma Or GED
No Income
$13K->$20K
$20K->$50K
$50K->$80K
$80K->$100K
$100K+
Below Federal Poverty Line (>$13K)
Family Addiction History
Family Alcohol History
History of Anxiety Disorders
History of Mood Disorders
Nicotine Dependence
Other Substance Use Diagnosis
Cannabis Use Disorder
DrugHelpSLI
SoughtMHHelpSLI
Use During Both Waves
Use in Wave 1 Only
Use in Wave 2 Only
No Use During Either Wave
a. The reference category is: No GAD.
b. This parameter is set to zero because it is redundant.
z

Null Model

OR (SE)

Sig.

OR (SE)

Sig.

-7.0469 (0.4328)

-

-7.1158 (0.4261)

-

1.268 (0.1432)

0.097

1.2734 (0.1426)

0.090

0.7963 (0.1796)

0.205

0.7968 (0.1795)

0.206

1.1008 (0.1644)

0.559

1.1006 (0.1643)

0.560

0.9062 (0.3732)

0.792

0.9095 (0.3721)

0.799

0.9909 (0.482)

0.985

1.0052 (0.4808)

0.991

b

b

0

-

0

-

<.01

<.001*

<.01

<.001*

1.1545 (0.382)

0.707

1.1738 (0.3818)

0.675

0.9998 (0.2072)

0.999

0.9945 (0.2071)

0.979

1.3715 (0.2421)

0.192

1.3772 (0.242)

0.186

1.1087 (0.162)

0.524

1.1042 (0.1619)

0.540

1.1187 (0.2127)

0.598

1.1269 (0.2125)

0.574

0.8465 (0.2081)

0.424

0.8525 (0.2078)

0.443

b

b

0

-

0

-

0.7729 (0.3034)

0.396

0.7755 (0.3032)

0.402

0.9924 (0.1866)

0.967

0.9874 (0.1865)

0.946

0.9275 (0.1463)

0.607

0.9335 (0.1461)

0.638

0.7534 (0.2448)

0.248

0.754 (0.2444)

0.248

0.5183 (0.6137)

0.284

0.5219 (0.6131)

0.289

0.6463 (0.4548)

0.337

0.6626 (0.4538)

0.364

0b

-

0b

-

1.312 (0.1388)

0.0503*

1.3149 (0.1383)

0.048*

1.2625 (0.1274)

0.067

1.2698 (0.1272)

0.060

4.3664 (0.1247)

<.001*

4.3717 (0.1246)

<.001*

6.2244 (0.141)

<.001*

6.1717 (0.1409)

<.001**

1.0303 (0.2683)

0.911

1.0184 (0.2675)

0.946

1.0703 (0.1352)

0.615

1.0573 (0.1347)

0.679

0.7261 (0.1734)

0.065

0.7702 (0.1659)

0.116

2.2677 (0.3093)

0.008*

2.138 (0.2923)

0.009*

15.374 (0.132)

<.001*

15.4781 (0.1318)

<.001*

0.8519 (0.3072)

0.602

-

-

0.4808 (0.4803)

0.127

-

-

0.9088 (0.2861)

0.738

-

-

0b

-

-

-
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Table 4: Multinomial Logistic Regression Cannabis Model and Null Model
No GAD Throughout compared to GAD at Wave 1 Portion
Cannabis Model
GAD Wave 1 Intercept
Sex
Hispanic
Black
American Indian/Alaska Native
Asian/Native Hawaiian/Other Pacific Islander
White
No Formal Schooling
Did Not Complete Middle School
Did Not Complete High School
Obtained Post-Grad Degree
Did Not Complete College
Obtained Associates or Technical Degree
Obtained Bachelor’s Degree
Obtained HS Diploma Or GED
No Income
$13K->$20K
$20K->$50K
$50K->$80K
$80K->$100K
$100K+
Below Federal Poverty Line (>$13K)
Family Addiction History
Family Alcohol History
History of Anxiety Disorders
History of Mood Disorders
Nicotine Dependence
Other Substance Use Diagnosis
Cannabis Use Disorder
DrugHelpSLI
SoughtMHHelpSLI
Use During Both Waves
Use in Wave 1 Only
Use in Wave 2 Only
No Use During Either Wave
a. The reference category is: No GAD.
b. This parameter is set to zero because it is redundant.
z
nn

Null Model

OR (SE)

Sig.

OR (SE)

Sig.

-4.6479 (0.2191)

-

-4.5986 (0.2141)

-

1.3842 (0.0708)

<.001*

1.3761 (0.0707)

<.001*

0.7229 (0.0926)

0.001*

0.7225 (0.0926)

<.001*

0.7986 (0.0886)

0.011*

0.7989 (0.0886)

0.011*

0.9262 (0.198)

0.699

0.9285 (0.198)

0.708

0.5923 (0.2556)

0.041*

0.5914 (0.2557)

0.040*

b

b

0

0

0.7906 (0.7262)

0.746

0.7865 (0.7262)

0.741

0.9714 (0.1978)

0.883

0.9656 (0.1978)

0.860

0.9652 (0.1073)

0.741

0.9646 (0.1072)

0.737

1.3264 (0.1184)

0.017*

1.3305 (0.1183)

0.016*

0.8931 (0.0869)

0.194

0.8945 (0.0869)

0.199

1.0784 (0.1084)

0.486

1.0802 (0.1083)

0.476

0.9389 (0.0998)

0.527

0.9413 (0.0997)

0.544

b

b

0

0

0.8628 (0.1552)

0.342

0.8613 (0.1553)

0.336

0.8752 (0.1002)

0.184

0.8732 (0.1002)

0.176

0.8288 (0.0776)

0.016*

0.8253 (0.0775)

0.013*

0.7788 (0.1158)

0.031*

0.7749 (0.1157)

0.028*

0.7678 (0.2305)

0.252

0.7588 (0.2304)

0.231

0.9798 (0.1798)

0.910

0.9728 (0.1796)

0.878

b

b

0

0

1.0716 (0.0776)

0.373

1.0759 (0.0775)

0.345

1.2501 (0.0651)

0.001*

1.2494 (0.0651)

0.001*

3.6782 (0.0632)

<.001*

3.67 (0.0632)

<.001*

5.5352 (0.0657)

<.001*

5.5467 (0.0656)

<.001*

0.9354 (0.1402)

0.634

0.9231 (0.1399)

0.567

1.2877 (0.0695)

<.001*

1.2956 (0.0692)

<.001*

0.8671 (0.0985)

0.148

0.8489 (0.0927)

0.077

1.2663 (0.2497)

0.344

1.348 (0.2441)

0.221

2.0917 (0.0753)

<.001*

2.0965 (0.0752)

<.001*

1.1071 (0.1701)

0.550

-

-

0.9913 (0.1941)

0.964

-

-

1.237 (0.1543)

0.168

-

-

-

-

0

b
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Table 5: Multinomial Logistic Regression Cannabis Model and Null Model
No GAD Throughout compared to GAD at Wave 2 Portion
Cannabis Model
GAD Wave 2 Intercept
Sex
Hispanic
Black
American Indian/Alaska Native
Asian/Native Hawaiian/Other Pacific Islander
White
No Formal Schooling
Did Not Complete Middle School
Did Not Complete High School
Obtained Post-Grad Degree
Did Not Complete College
Obtained Associates or Technical Degree
Obtained Bachelor’s Degree
Obtained HS Diploma Or GED
No Income
$13K->$20K
$20K->$50K
$50K->$80K
$80K->$100K
$100K+
Below Federal Poverty Line (>$13K)
Family Addiction History
Family Alcohol History
History of Anxiety Disorders
History of Mood Disorders
Nicotine Dependence
Other Substance Use Diagnosis
Cannabis Use Disorder
DrugHelpSLI
SoughtMHHelpSLI
Use During Both Waves
Use in Wave 1 Only
Use in Wave 2 Only
No Use During Either Wave
a. The reference category is: No GAD.
b. This parameter is set to zero because it is redundant.
z

Null Model

OR (SE)

Sig.

OR (SE)

Sig.

-4.5473 (0.2167)

-

-4.4516 (0.2113)

-

1.569 (0.0745)

<.001*

1.5557 (0.0743)

<.001*

0.9066 (0.0889)

0.270

0.9073 (0.0889)

0.274

1.1014 (0.0834)

0.246

1.1035 (0.0833)

0.237

1.0061 (0.2187)

0.978

1.0118 (0.2185)

0.957

0.9115 (0.2284)

0.685

0.9142 (0.2284)

0.694

0b

0b

1.5658 (0.4453)

0.314

1.5537 (0.4452)

0.322

1.1604 (0.1827)

0.416

1.1493 (0.1827)

0.446

1.1834 (0.107)

0.116

1.1877 (0.1069)

0.108

1.0511 (0.1399)

0.722

1.0554 (0.1398)

0.700

1.0913 (0.089)

0.326

1.0977 (0.089)

0.295

1.1754 (0.1138)

0.156

1.1755 (0.1138)

0.155

1.0833 (0.1023)

0.435

1.0877 (0.1023)

0.411

0b

0b

0.9269 (0.153)

0.620

0.9245 (0.153)

0.608

0.9484 (0.1019)

0.604

0.9452 (0.1019)

0.580

0.9546 (0.079)

0.557

0.9493 (0.0789)

0.510

0.7075 (0.1292)

0.007*

0.7002 (0.1291)

0.006*

1.0421 (0.2313)

0.859

1.0278 (0.231)

0.906

0.8551 (0.2045)

0.444

0.8419 (0.2044)

0.400

b

b

0
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Discussion
The current study aimed to address the ongoing debate about the relationship between
cannabis use and anxiety by specifically focusing on GAD. The study sought to answer whether
meeting criteria for GAD could be significantly affected by initiation, continuation, or cessation
of cannabis use in a nationally representative longitudinal sample. Findings suggested cannabis
use did not significantly predict or affect meeting criteria for GAD throughout the study, or in
wave 1 or wave 2 exclusively. When the full model was compared to the null model, the full
model with the cannabis use covariates did not account for any additional variance, and yielded
the worse model fit estimates, suggesting the best fitting and most parsimonious model would be
the null model.
Failure to find significant results for the hypothesis has several implications. Primarily,
the finding that different cannabis use trajectories did not significantly predict GAD status
suggests that initiation, continuance, or cessation of cannabis use may not increase the odds of
meeting criteria for GAD within a 3-year period differently than for those participants who did
not use at all during the study. Additionally, the lack of significant findings can ameliorate fears
that decriminalizing cannabis use will lead to an increase in individuals developing GAD.
Although the effects of the initiation of cannabis use and risk factors have been studied in the
past, different research methods and updated diagnostic criteria have affected the quality and
validity of previous research. Future research should seek to examine how predictors of cannabis
initation and use are related to predictors of GAD status.
Despite failing to find support for the hypothesis, several significant secondary
relationships were found. There were three predictors that remained significant at all levels of
GAD when compared to particpants who did not have GAD throughout: history of mood
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disorder, history of anxiety disorder, and seeking help for mental health. The mood and anxiety
disorders evaluated in this study were: major depression, dysthymia, manic depression,
hypomanic disorder, panic disorder with and without agoraphobia, agoraphobia, social phobia,
and specific phobia. The finding that history of mood or anxiety disorders was a significant
predictor of GAD status for participants is consistent with previous findings highlighting
comorbidity between these anxiety and mood disorders (Byers, Yaffe, Covinsky, Friedman, &
Bruce, 2010). The finding that seeking help for mental health between waves was a significant
predictor for all levels of GAD is consistent with research on expectancy theory. Expectancy
theory suggests that individuals become more anxious when they anticipate anxiety or as a result
of the fear of anxiety (Taylor, Koch, & McNally, 1992). These findings may be explained by the
expectancy theory relating to seeking help for mental health. Future research should further
examine the role of anticipating anxiety in cannabis use and on the presentation of GAD.
The remaining covariate relationships were not significant predictors at each level of
GAD. Sex was a significant predictor of meeting criteria for GAD at wave 1 and 2, such that
women had higher odds of meeting criteria for GAD. This finding is consistent with research
findings that indicate women experience anxiety disorders at a higher frequency than men
(Angst, & Dobler-Mikola, 1985; Bruce et al, 2005). Other substance use and familial substance
use were also significant predictors. When compared to participants who did not meet criteria for
GAD throughout the study, family history of alcohol abuse was a significant predictor of
meeting criteria for GAD throughout and family addiction history was a significant predictor of
meeting criteria for GAD at wave 1. This finding is consistent with research that has found
history of family addiction or alcoholism were key factors in the presence or absence of various
disorders, including anxiety and mood disorders (Milne et al., 2009; Hayatbakhsh 2007).
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Participants who engaged in other substance use at wave 1 or wave 2 had higher odds of meeting
criteria for GAD when compared to those who did not meet criteria throughout. Additionally,
participants who reported nicotine dependence had higher odds of meeting criteria for GAD at
wave 2 when compared to participants who did not have GAD throughout. These findings are
consistent with studies that have found other substance use and nicotine use is associated with
higher risk of having anxiety or experiencing anxiety-related symptoms (Hayatbakhsh 2007).
This study’s use of archival data presented several limitations. Primarily, the data was
collected between 2001-2002 and 2003-2004, representing a 3-year span. It is possible that a
longer timeframe or more frequent intervals may have resulted in better dectection and testing of
the relationship between cannabis use and GAD diagnosis. Further, research has found that the
relationship between cannabis use and GAD may be dose dependent (Crippa et al., 2009).
However, the dataset did not include information on how consistently cannabis was used, and
determined frequency based on instances of use, creating a limitation on the analyses that could
be conducted. Future studies should use a controlled experiment design to understand the
relationship between initation and use of cannabis and how its frequency and consistency of use
are related to meeting criteria for GAD. Future studies should also further examine how different
usage frequencies affect whether cannabis is an effective treatment for GAD, if at all.
The use of NESARC data presented other limitations for this study. NESARC is a threewave study, however, during the time between wave 2 data collection ending and wave 3 data
collection starting, the diagnostic and statistical manual had been revised from version 4-TR to
version 5 (American Psychiatry Association, 2013). Data collected in wave 1 and 2 are no longer
aligned with the diagnostic categories in the newest version, which limited generalizeability.
Additionally, NESARC collected cannabis use data using a self-report measure, which has been
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shown to suppress reporting due to the sensitivity of the topic (Van der Linden, 2017), perhaps as
a result only a small subset of the sample reported using cannabis. The sample subset of
participants who met criteria for GAD was also small. The small sample sizes were compared to
larger sample sizes (e.g. No GAD) and may not be statistically representative of relationship
between individuals who engage in cannabis use and meet criteria for GAD. However, it is
important to note that there was great variability in the samples sociodemographic information
(e.g. age, income level, education level, and ethnicity) as a result of NESARC’s nationally
representative sample. Lastly, the NESARC cohort represents individuals who were born in 1915
through 1985, during this timeframe cannabis use was available over-the-counter, was
criminalized, and has recently begun to become decriminalized. This cohort, although currently
representative, may not reflect the change in social attitudes toward the use of cannabis, and may
not reflect the impact of the changes in legislation. Future research should collect data from a
later birth cohort and compare cannabis use trends to understand the impact of the cohort effect
on cannabis use.
The finding that cessation or initiation of cannabis use during a 2-year period does not
increase or decrease the likelihood of meeting criteria for GAD has several implications.
Primarily, these findings add evidence against the theory that there is a cause and effect
relationship between GAD and cannabis use. Additionally, these findings serve to ameliorate
concerns that increased legalization would lead to an increase in rates of GAD. Despite the
limitations, this study contributes research to an area that needs further exploration, the
relationship between GAD and cannabis use, during a time in which the information can be
directly utilized to make informed decisions.
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